ONCOLOGY Nurse Edition April 2009, Vol 23 No 4

Publication
Article
Oncology Nurse EditionONCOLOGY Nurse Edition Vol 23 No 4
Volume 23
Issue 4

Main Articles

Departments

Patient Information

  • Understanding and Managing Nausea and Vomiting

 

 

Articles in this issue
ONCOLOGY Nurse Edition April 2009, Vol 23 No 4
Hypertension Management in the Era of Targeted Therapies for Cancer
An Alkylating Agent for CLL and NHL
Vesicant Extravasation From an Implanted Venous Access Port
Survivorship Care: Essential Components and Models of Delivery
Cardiotoxicities of Breast Cancer Treatment
Improving the End-of-Life Experience
When Hospice Is the Best Option: An Opportunity to Redefine Goals
Living Well: A Goal for All Patients
The Patient With Cancer-Related Dyspnea
Recent Videos
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
2 experts are featured in this series.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
Related Content
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?

What is the Impact of the SHARON Trial on Pancreatic Cancer Research?

Ariana Pelosci
October 29th 2025
Article

Kenneth H. Yu, MD, discusses the results from the SHARON trial in pancreatic cancer that were presented at ESMO 2025.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

The phase 3 KEYNOTE-689 trial showed a median EFS of 59.7 months with the pembrolizumab regimen in locally advanced head and neck squamous cell carcinoma.

Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group

Tim Cortese
October 29th 2025
Article

The phase 3 KEYNOTE-689 trial showed a median EFS of 59.7 months with the pembrolizumab regimen in locally advanced head and neck squamous cell carcinoma.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

3 Things You Should Know About Single-Agent ADCs in TNBC Treatment

ONCOLOGY Staff
October 29th 2025
Article

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

JSKN003 Receives FDA Fast Track Designation in Advanced PROC

Roman Fabbricatore
October 28th 2025
Article

The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.